Epioxa Shows Durable 3-Year Keratoconus Outcomes in Phase 3 Extension
GKOS has more than doubled off its 52-week low of $73.16.
Summary
Glaukos reported positive three-year extension data for Epioxa, its epi-on corneal cross-linking therapy for keratoconus. Treated eyes sustained a 1.9 diopter improvement in Kmax and meaningful visual acuity gains, with 29% gaining two or more lines and 20% gaining three or more lines. No serious adverse events or discontinuations were reported. This long-term durability data strengthens the commercial case for Epioxa, which is already FDA-approved and marketed. The results follow strong Q2 sales growth and raised guidance, reinforcing the company's pipeline momentum.
At the time of this announcement, GKOS was trading at $172.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $73.16 to $191.62. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.